Skip to content

The influence of rehydration and the antidiuretic hormone on blood coagulation in the dehydrated patient

The influence of rehydration and the antidiuretic hormone on blood coagulation in the dehydrated patient - ADH study- part 1

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON36118
Enrollment
12
Registered
2011-07-12
Start date
2011-07-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vochthuishouding dehydration fluid deficiency

Interventions

None listed

Sponsors

Slotervaartziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: a. Adults >= 18 years old. b. Able to provide informed consent. c. Confirmed infection of any cause (for 6 patients)

Exclusion criteria

Exclusion criteria: a. Strong suspection of an infection of any cause (for 6 patients) see definition of infection b. Primary polydipsia and diabetes insipidus. c. Untreated thyroid and adrenal hormone abnormalities. d. Pregnancy or puerperium. e. Common etiologies of the syndrome of inappropriate antidiuretic hormone (SIADH); Active malignancy, inflammatory diseases (multiple sclerosis, meningitis, systemic lupus erythematosus), acquired immuno- deficiency syndrome (AIDS), infections (tuberculosis, pneumonia, empyema) (only for those 6 patients without signs of infection), cystic fibrosis, drugs (Selective serotonine reuptake inhibitors, tricyclic antidepressants, carbamazepine, clofibrate, narcotics, antipsychotic drugs, cytotoxic drugs) f. Potentiation of AVP antidiuretic effects: desmopressin, vasopressin, oxytocin, prostaglandin synthesis inhibitors

Design outcomes

Primary

MeasureTime frame
Coagulation and fibrinolysis activation markers: F1+2 (fragment 1+2), ETP (endogenous thrombin potential), D-dimer, Plasminogen Activator Inhibitor-1 (PAI-1) activity. Endothelial cell activation and platelet activation markers: von Willebrand factor activity (vWf:C), clotting factor VIII activity (fVIII:C). Blood coagulation time: PT.

Secondary

MeasureTime frame
urine osmolality, plasma osmolality, antidiuretic hormone, hematocrit.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)